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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the benefits and safety of tourniquets used in knee replacement surgery.
B A C K G R O U N D
Description of the condition
Approximately one in two people develop symptomatic knee
arthritis before the age of 85 (Murphy 2008). Knee replacement
is an effective surgical procedure performed for the relief of pain
from end-stage arthritis (Skou 2016). Knee replacement surgery
is routinely undertaken with the aid of a tourniquet around the
thigh during the procedure (Gibbs 2016).
Description of the intervention
A thigh tourniquet is an occlusive device which squeezes the upper
leg and restricts distal blood flow.
Types
There are two broad designs of thigh tourniquet used for knee
replacement surgery:
1. Inflatable/pneumatic: a cuff placed around the thigh is filled
with compressed gas. The pressure in the cuff is maintained by a
microprocessor and can be adjusted.
2. Non-inflatable: a rubber or elasticated cloth ring is placed
around the thigh. A device which achieves the required pressure
is applied and can not be adjusted unless it is replaced with a new
device.
Prior to the tourniquet being applied, the leg can be elevated or
exsanguinated (using a bandage or similar device), to help reduce
the amount of pooled blood within the leg.
Duration
A thigh tourniquet can be used for the duration of the procedure
or for part of the procedure (for example, just during knee replace-
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ment component cementation only).
A 2010 survey found that 95% of surgeons in the USA use a
tourniquet for knee replacement surgery (Zhang 2014), and the
UK’s National Joint Registry (NJR) reported that 93% of primary
knee replacements were done with a tourniquet in 2003 (National
Joint Registry 2004).
How the intervention might work
The tourniquet is designed to apply pressure to the thigh above the
internal pressure of local blood vessels (limb occlusion pressure),
thereby restricting both arterial and venous blood flow distally.
Why it is important to do this review
Although the effects of using a tourniquet have been the subject
of systematic reviews before (Alcelik 2012; Smith 2010; Tai 2011;
Zhang 2014), not all the important outcomes have been described,
reviewed and evaluated together. These include:
Potential benefits
Surgical field of view
Using a tourniquet may improve the surgical field of view by lim-
iting intraoperative blood loss (Zhang 2014).
Cementation
Most knee replacement components are cemented in place to hold
and stabilise them in the correct position on the bone. Cement
which is initially soft when it is inserted interdigitates into the
porous bone, forming a strong bond to the bone as it sets. Some
surgeons believe that using a tourniquet helps reduce bleeding
from the porous bone ends and allows the soft cement to bond
more effectively, and as a result improves the long-term survival
of the knee implant components (Grewal 1992; Pfitzner 2016).
Blood loss
One previous systematic review (Alcelik 2012) showed that intra-
operative blood loss was less when a tourniquet was used. However,
when another group reviewed overall blood loss (Zhang 2014),
there was no difference between intervention groups.
Potential risks
Pain and function
A tourniquet which is often applied for the duration of the pro-
cedure and tightly squeezes the thigh can cause pain both dur-
ing and after surgery (Abdel-Salam 1995). In addition to pain, a
tourniquet can cause bruising and swelling to the thigh muscles
which it squeezes. These muscles are important for mobilisation
and therefore can inhibit postoperative function.
Venous Thrombo Embolism (VTE)
A tourniquet causes both arterial and venous stasis within the lower
leg for the duration that it is inflated (typically over an hour). It
is therefore possible that the use of a surgical tourniquet might
increase the risk of postoperative venous thromboembolism (VTE)
(Tai 2011; Wauke 2002; Zhang 2014).
Systemic Emboli
VTE may not be the only thromboembolic risk associated with
using a tourniquet. Systemic emboli can occur following the de-
flation of a tourniquet (Berman 1998). Transoesophageal echocar-
diography has demonstrated shower-like echogenic materials cir-
culating from the lower limbs to the right atrium, ventricle, and
pulmonary artery after the release of a thigh tourniquet, and also
macroscopic emboli in the central circulation (Berman 1998). As
the carotid arteries are the first branches from the aortic arch in a
straight-line orientation, some of these clots may enter the cere-
bral circulation. Transcranial Doppler ultrasound studies show a
60% prevalence of echogenic material in the Circle of Willis after a
tourniquet is released, and that microemboli can occur even in the
absence of a patent foramen ovale (connection between the left and
right side of the circulation within the heart) (Sulek 1999). The
most likely route for emboli in these circumstances is through the
pulmonary capillaries or the opening of other pulmonary vessels
(Sulek 1999). The critical time is immediately after release of the
tourniquet, when there is potential haemodynamic instability and
evidence to suggest a five-fold increase in the amount of embolic
material (Huh 2012; Parmet 1998). The presence of cerebral em-
boli which can cause cerebral damage may explain the higher than
expected prevalence of postoperative cognitive deficit following
total knee replacement (TKR). In the literature this varies from
41% to 75% at seven days to 18% to 45% at three months post-
operatively (Deo 2011). These percentages are much higher than
those recorded in other major lower-limb procedures with similar
types of anaesthetic, but where a tourniquet is not used (Koch
2007).
Other effects
Alcelik 2012 concluded that minor complications were more com-
mon when a tourniquet is used; similarly, Zhang 2014 showed
reduced complications, including infection, blister, haematoma,
wound oozing, bruising, nerve palsy and re-operation.
We propose a review of the effects of tourniquet use during TKR
surgery which, in addition to measuring effects on pain, function,
quality of life and blood loss, will capture field of view, cognitive
function, adverse events including VTE, systemic emboli (includ-
ing cerebral stroke), revision surgery and death.
O B J E C T I V E S
To determine the benefits and safety of tourniquets used in knee
replacement surgery.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised
We will include studies in which participants are randomised to
intervention groups and studies in which allocation to interven-
tions are quasi-randomised (i.e. not strictly random, for example
by date of birth, hospital record number or alternation).
Non-randomised
Randomised studies, particularly in the field of this review, are
unlikely to include more than 1000 participants. To help improve
estimates of the potential risks, e.g. adverse events of the interven-
tion, many of which may be rare events (VTE approximately <
5% (Zhang 2014)), we will include the following non-randomised
study types:
• Observational cohort studies and unselected case series of
1000 or more participants, which include concurrent
comparison groups, e.g. published data from joint replacement
registries, for example the National Joint Registry 2015.
To minimise selection bias within non-randomised studies, we will
include only studies that use statistical adjustment for baseline case
mix, e.g. multivariable analyses to adjust for age, comorbidity and
type of knee replacement (unicondylar knee replacement, total
knee replacement, primary or revision).
Types of participants
We will include participants who are undergoing knee replace-
ment surgery for any indication, regardless of age. We will include
all types of knee replacement, including partial (e.g. unicondylar,
patellofemoral) and revision surgery.
Types of interventions
We will include studies of all types of thigh tourniquet (inflatable
or non-inflatable) used for the duration or part of the knee re-
placement surgery. Comparators could be:
1. Placebo: this may include a sham tourniquet, for example one
that is applied but not inflated.
2. No tourniquet
3. Alternative measures to improve the surgical field of view or
reduce intraoperative blood loss, e.g. this may include tranexamic
acid.
Types of outcome measures
Major outcomes
According to the OMERACT core outcome set (Bellamy 1997),
pain, function/disability, global assessment of success and health-
related quality of life are the major outcomes. We will prioritise
them according to previous evidence on the hierarchy of patient-
reported outcomes (Juhl 2012).
1. Pain
Measured using mean pain or mean change in pain, on a visual
analogue scale (VAS), a numerical rating scale or another scale.
2. Function
Measured with instruments such as: Knee Society Score (KSS),
Western Ontario and McMaster Universities Arthritis Index
(WOMAC), Knee Injury and Osteoarthritis Outcome Score
(KOOS), Oxford Knee Score (OKS). We will extract all available
function scores and present total scores in the primary analysis and
subscores as additional analyses when available.
3. Global assessment of success
As reported by the participant, e.g. proportion of participants re-
porting overall successful treatment and participant satisfaction.
4. Health-related quality of life
Measured with instruments such as Short Form-36 (SF-36), or
EuroQoL 5D (EQ-5D).
We will also assess the following as major outcomes:
5. Serious Adverse events (SAE)
A serious adverse event is an adverse event that fulfils one of more
of the following criteria: results in death, immediately life-threat-
ening, requires hospitalisation or prolongation of existing hospi-
talisation, or is an important medical condition. We will report
the complications and morbidity associated with the use (nerve
damage, ischaemia, bruising and pain) or non-use of tourniquets
(e.g. death, deep-joint infection, VTE, systemic emboli and re-
operation, excluding revision for implant failure).
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6. Cognitive function
Measured with instruments such as Mini-Mental State Exami-
nation (MMSE), Oxford Cognitive Screen (OCS) and Montreal
Cognitive Assessment (MoCA).
7. Survival of the implant
Measured as time to failure. The preferred marker of implant fail-
ure will be revision surgery.
We will prioritise the major outcomes in numerical order, as given
above.
Minor outcomes
Following discussion between the senior review authors, we will
prioritise the minor outcomes in numerical order as shown below.
1. Blood loss:
a) Total blood loss during surgery (intra-operative blood loss).
b) Postoperative blood loss measured from drainage systems and
blood transfusion rates.
Example outcome measures include: change in haematocrit,
change in haemoglobin level and number of units of postoperative
blood transfusions.
2. Economic
a) Resource usage: direct healthcare and societal costs, to facilitate
a cost-effectiveness analysis.
b) Duration of surgery: we will report the definition of surgery
start and finish times where available.
c) Length of hospital stay.
3. Implant stability: v
Validated methods such as radiostereometric analysis (RSA).
4. Adverse events
We will report adverse events which are not classified as serious
adverse events, based on the criteria above.
Timing of outcome assessment
Studies are likely to report the outcomes discussed at several time
points. We therefore plan to group these assessments into three cat-
egories: short-term (up to and including three months), medium-
term (after three months and up to and including 12 months) and
long-term follow-up (greater than one year).
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE and Embase.
We will also conduct a search of ClinicalTrials.gov and the WHO
trials portal (www.who.int/ictrp/en/).
We will search all databases from their inception to the present,
and will impose no restriction by language of publication.
See Appendix 1 for the MEDLINE search strategy for RCTs.
See Appendix 2 for the MEDLINE search strategy for observa-
tional studies
Searching other resources
We will check reference lists of all primary studies and review
articles for additional references.
We will search the following established joint registry programmes
for relevant published reports and use these contacts to identify
any missing joint registry programmes:
Australasia
Australian Orthopaedic Association National Joint Replacement
Registry: aoanjrr.sahmri.com/
New Zealand National Joint Register: nzoa.org.nz/nz-joint-
registry
Europe
Danish Knee Arthroplasty Register: www.kea.au.dk/en/
ClinicalQuality/KneeArthroplastyRegistry.html
European Arthroplasty Register: www.ear.efort.org/
Scottish Arthroplasty Project: www.arthro.scot.nhs.uk/
Slovak National Arthroplasty Register: sar.mfn.sk/the-slovak-
arthroplasty-register.348.html
Swedish Knee Arthroplasty Register: www.myknee.se/en/
National Joint Registry of England and Wales:
www.njrcentre.org.uk/njrcentre/default.aspx
Norwegian Arthroplasty Register: nrlweb.ihelse.net/eng/
Portugese Arthroplasty Register: www.rpa.spot.pt/
RIPO Bologna, Italy: ripo.cineca.it/
Romanian Arthroplasty Register: www.rne.ro/?lang=en
North America
American Joint Replacement Registry: www.ajrr.net/
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Canadian Joint Replacement
Register: www.cihi.ca/en/types-of-care/specialized-services/joint-
replacements/canadian-joint-replacement-registry
Health East Joint Replacement Registry: www.healtheast.org/
orthopaedics/registry.html
Kaiser Permanente National Implant Registries:
www.kpimplantregistries.org/
Western Slope Study Group: www.wssgco.com/
We will search for errata or retractions from included studies pub-
lished in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed)
and report the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (IA and PW) will independently screen ti-
tles and abstracts of all the potential studies for inclusion that we
identify as a result of the search. We will code them as ’retrieve’
(eligible or potentially eligible/unclear) or ’do not retrieve’. After
retrieving the full-text study reports/publications, two review au-
thors (IA and PW) will independently screen them and identify
studies for inclusion, and will identify and record reasons for ex-
clusion of the ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third review
author (MU). We will identify and exclude duplicates and collate
multiple reports of the same study, so that each study, rather than
each report, is the unit of interest in the review. We will record the
selection process in sufficient detail to complete a PRISMA flow
diagram and ’Characteristics of excluded studies’ table.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data which has been piloted on at least one study in the
review. One review author (IA) will extract study characteristics
from the included studies. A second review author (PW) will cross-
check study characteristics for accuracy against the trial report. We
will extract the following study characteristics:
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and dates of study.
2. Participants: number (N), mean age, age range, sex, disease
duration, comorbidities, inclusion criteria, and exclusion criteria.
3. Interventions: type of surgery, number of participants in
tourniquet group, number of participants in comparator group
(sham/no tourniquet/other).
4. Outcomes: major and minor outcomes specified and
collected, and time points reported.
5. Characteristics of the design of the trial as outlined in the
Assessment of risk of bias in included studies section below.
6. Notes: funding for trial, and notable declarations of interest
of trial authors.
Two review authors (IA and PW) will independently extract out-
come data from the included studies. We will extract the number
of events and number of participants in each treatment group for
dichotomous outcomes, and means and standard deviations and
number of participants in each treatment group for continuous
outcomes. For non-randomised trials we will extract adjusted out-
come measures.
We aim to use non-randomised studies to extract outcomes of
interest which are rare, for example: VTE and implant failure rate.
We will note in the ’Characteristics of included studies’ table if
outcome data were not reported in a usable way and when data
were transformed or estimated from a graph. We will resolve dis-
agreements by consensus or by involving a third review author
(MU). One review author (IA) will transfer data into the Review
Manager 5 file (RevMan 2014). We will double-check that data
are entered correctly by comparing the data presented in the re-
view with the study reports.
Our a priori decision rules to extract data in the event of multiple
outcome reporting in trials are as follows:
Where trialists report both final values and change from baseline
values for the same outcome, we plan to extract change from base-
line values.
Where trialists report both unadjusted and adjusted-for-baseline
values for the same outcome, we plan to extract unadjusted baseline
values.
Where trialists report data analysed based on the intention-to treat
(ITT) sample and another sample (e.g. per protocol, as treated),
we plan to extract ITT-analysed data.
Where trials do not include a measure of overall pain but include
one or more other measures of pain, for the purpose of pooling
data we will combine overall pain with other types of pain in
the following hierarchy: unspecified pain, pain at rest, pain with
activity, or daytime pain.
Where trialists report multiple pain outcome measures, for the
purposes of pooling data we will extract one measure using the
following hierarchy: visual analogue scale, numerical or cognitive
rating scale, McGill pain questionnaire, or other scale.
Where trialists report multiple measures of function or disability,
for the purposes of pooling data we will extract a single measure
using the following hierarchy: Oxford knee score (OKS), Knee
Injury and Osteoarthritis Outcome Score (KOOS), Knee Society
Score (KSS), Western Ontario and McMaster Universities Arthri-
tis Index (WOMAC) or other scale.
Assessment of risk of bias in included studies
Randomised studies
Two review authors (IA and PW) will independently assess risks
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
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We will resolve any disagreements by discussion or by involving
another review author (MU). We will assess the risks of bias ac-
cording to the following domains:
1. Random sequence generation (only for randomised studies).
2. Allocation concealment (only for randomised studies).
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other potential bias, e.g. discrepancies between groups for
comorbidities which could act as confounding factors, for
example clotting disorders.
We will grade each potential source of bias as high, low or unclear,
and will provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the risk of bias judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes where necessary (e.g. for unblinded
outcome assessment, risk of bias for all-cause mortality may be
different than for a participant-reported pain scale). We will also
consider the impact of missing data by key outcomes.
Where information on risk of bias relates to unpublished data or
correspondence with a trialist, we will note this in the ’Risk of bias’
table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
We will present the figures generated by the ’Risk of bias’ tool to
provide summary assessments of the risks of bias.
Non-randomised studies
We will use ROBINS-I, a tool for assessing risk of bias in non-
randomised studies of interventions (Sterne 2016). This will in-
volve three stages for each study:
Stage 1
Specify the research question, list the confounding domains, list
co-interventions and specify the outcomes you are collecting.
Confounding factors which may influence outcomes include:
1. Comorbidities such as vascular disease;
2. Previous VTE disease;
3. Prothombotic conditions such as malignancy;
4. Use and type of VTE prophylaxis (such as low molecular
weight heparin, aspirin, intermittent calf pump);
5. Type of implant used;
6. Use of cement;
7. Basic participant demographics, including age, body mass
index (BMI), and American Society of Anaesthesiologists (ASA)
grade.
Stage 2
Risk of bias assessment for specific result.
Stage 3
Overall risk of bias assessment, ’triangulated’ across studies.
The tool will evaluate the following areas of bias:
1. Confounding
2. Selection bias
3. Bias in measurement classification of interventions
4. Bias due to deviations from intended interventions
5. Bias due to missing data
6. Bias in measurement of outcomes
7. Bias in selection of the reported result
We will report bias as low risk of bias, moderate risk of bias, serious
risk of bias, critical risk of bias, no information.
Assesment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and will report any deviations from it in the ’Differences between
protocol and review’ section of the review.
Measures of treatment effect
We will use risk ratios (RRs) with a 95% confidence intervals
(CI) to report categorical outcomes. We will analyse continuous
data as the mean difference (MD) or standardised mean difference
(SMD), depending on whether the same scale is used to measure
an outcome, with a 95% confidence interval. We will enter data
presented as a scale with a consistent direction of effect across
studies.
When different scales are used to measure the same conceptual
outcome (e.g. disability), we will calculate the SMDs, with a cor-
responding 95% CI. We will back-translate the SMD to a typical
scale (e.g. 0 to 10 for pain) by multiplying the SMD by a typical
among-person standard deviation (SD), e.g. the standard devia-
tion of the control group at baseline from the most representa-
tive trial, as described in Chapter 12 of the Cochrane Handbook
(Schünemann 2011b).
For non-randomised studies we will assess the treatment effect
using the risk ratio, provided the follow-up periods are consistent
and we are reporting categorical data.
In the ’Effects of intervention’ Results section and the ’Comments’
column of the ’Summary of findings’ table we will provide the ab-
solute per cent difference, the relative per cent change from base-
line, and the number needed to treat for an additional beneficial
outcome (NNTB); we will calculate the NNTB only when the
outcome shows a statistically significant difference.
For dichotomous outcomes, such as serious adverse events, we
will calculate the NNTB from the control group event rate
and the risk ratio, using the Visual Rx NNT calculator (Cates
2008). We will calculate the NNTB for continuous measures us-
ing the Wells calculator (available at the CMSG Editorial office,
musculoskeletal.cochrane.org/).
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For dichotomous outcomes, we will derive the absolute risk differ-
ence using the Risk Difference statistic in Review Manager 5, and
will express the result as a percentage. For continuous outcomes,
we will calculate the absolute risk difference as the improvement
in the intervention group minus the improvement in the control
group, in the original units.
We will calculate the relative per cent change for dichotomous
data as the RR minus 1, expressed as a percentage. For continuous
outcomes, we will calculate the relative difference in the change
from baseline as the absolute benefit divided by the baseline mean
of the control group.
Unit of analysis issues
We expect most studies to be simple parallel-group designs. How-
ever, if we find other designs (e.g. cluster-randomised), we will use
generic inverse variance methods to combine data. For analysis,
we plan to use details of intra-class correlation coefficients (ICCs)
and cluster sizes for trials of this type, if reported effects have not
been adjusted for clustering.
Where multiple trial arms are reported in a single trial, we will
include only the relevant arms. If two comparisons are combined
in the same meta-analysis, we will halve the control group to avoid
double-counting.
We do not expect any crossover trials, but if we do include them
we will report the findings at the end of the first treatment period
only.
We will prefer trials that report a unit of analysis at the participant
level, to maintain independence of the outcome variable.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as abstract only,
or when data are not available for all participants). Where this is
not possible, and the missing data are thought to introduce serious
bias, we will explore the impact of including such studies in the
overall assessment of results by a sensitivity analysis. We will clearly
describe any assumptions and imputations for handling missing
data, and will explore the effect of imputation by sensitivity anal-
yses.
For dichotomous outcomes (e.g. number of withdrawals due to
adverse events), we will calculate the withdrawal rate using the
number of participants randomised in the group as the denomi-
nator.
For continuous outcomes (e.g. mean change in pain score), we will
calculate the MD or SMD based on the number of participants
analysed at that time point. If the number of participants analysed
is not presented for each time point, we will use the number of
randomised participants in each group at baseline.
Where possible, we will compute missing standard deviations from
other statistics such as standard errors, confidence intervals or P
values, according to the methods recommended in the Cochrane
Handbook for Systematic Reviews of Interventions. If we cannot es-
timate standard deviations, we will impute them (e.g. from other
studies in the meta-analysis).
Assessment of heterogeneity
We will assess clinical and methodological diversity in terms of
participants, interventions, outcomes and study characteristics for
the included studies, to determine whether a meta-analysis is ap-
propriate. We will assess statistical heterogeneity by visual inspec-
tion of the forest plot to assess for obvious differences in results
between the studies, and by using the I2 and Chi2 statistical tests.
As recommended in the Cochrane Handbook (Deeks 2011), the
interpretation of an I2 value of 0% to 40% ’might not be im-
portant’; 30% to 60% may represent ’moderate heterogeneity’;
50% to 90% may represent ’substantial heterogeneity’; and 75%
to 100% represents ’considerable heterogeneity’. As noted in the
Cochrane Handbook, we will keep in mind that the importance of
I2 depends on the magnitude and direction of effects and on the
strength of evidence for heterogeneity.
We will interpret a Chi2 test with a P value of 0.10 or less as
evidence of statistical heterogeneity.
If we identify substantial heterogeneity we will report it and inves-
tigate possible causes by following the recommendations in sec-
tion 9.6 of the Cochrane Handbook.
Assessment of reporting biases
We will create and examine a funnel plot to explore possible small-
study biases. In interpreting funnel plots, we will examine the
different possible reasons for funnel plot asymmetry, as outlined
in section 10.4 of the Cochrane Handbook, and relate this to the
results of the review. If we are able to pool more than 10 trials,
we will undertake formal statistical tests to investigate funnel plot
asymmetry, and will follow the recommendations in section 10.4
of the Cochrane Handbook (Sterne 2011).
To assess outcome reporting bias, we will check trial protocols
against published reports. For studies published after 1st July 2005,
we will screen the Clinical Trial Register at the International Clin-
ical Trials Registry Platform of the World Health Organization (
apps.who.int/trialssearch) for the a priori trial protocol. We will
evaluate whether selective reporting of outcomes is present.
Data synthesis
We will pool outcomes of clinically and methodologically homo-
geneous studies, where meaningful, using a random-effects model.
We will perform analysis using Review Manager 5 and will pro-
duce forest plots for all analyses.
We will only pool outcomes of non-randomised studies if the
studies are clinically homogeneous, using a random-effects model
which will allow for different study variances. We will use log-RR
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data (with corresponding standard errors (SEs) on the log scale)
and will pool outcomes using the generic inverse variance method.
We will use non-randomised studies to analyse only outcomes
which are rare, for example VTE and implant failure rate. We will
assess clinical homogeneity based on participants, intervention
(procedure performed with a tourniquet), outcomes (VTE and
implant failure) and study characteristics, including study design.
Two review authors (IA and PW) will determine if at least three
of these features are matching between each study in order to pool
the data.
’Summary of findings’ table
We will create a ’Summary of findings’ (SoF) table using the fol-
lowing outcomes:
1. Pain
2. Function
3. Global assessment of success
4. Health-related quality of life
5. Serious adverse events
6. Cognitive function
7. Survival of the implant
The comparison in the first SoF table will be:Tourniquet versus
no tourniquet. For the second SoF table the comparator will be:
Tourniquet versus sham tourniquet.
Two review authors (IA and PW) will independently assess the
quality of the evidence. We will use the five GRADE considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of a body of
evidence as it relates to the studies which contribute data to the
meta-analyses for the prespecified outcomes. We will use methods
and recommendations described in Section 8.5, 8.7, Chapter 11
and Chapter 13 section 13.5 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011; Schünemann 2011a),
using GRADEpro software. We will justify all decisions to down-
or upgrade the quality of studies using footnotes, and we will make
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Different surgical procedures that may affect outcome, e.g.
unicompartmental knee replacement, primary knee replacement
and revision knee replacement.
2. Different types of tourniquet that may affect outcome, e.g.
inflatable or non-inflatable.
3. Duration of tourniquet use that may affect outcome, e.g.
used for the whole procedure or used for part of the procedure.
We will do this by predefining subgroups based on stages of the
procedure.
The types of surgical procedure vary in complexity and may there-
fore impact upon both the duration of tourniquet use and the risk
of complications.
We will use the following outcomes in subgroup analyses:
1. Pain
2. Function
3. Adverse events
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014), and will use caution in the interpreta-
tion of subgroup analyses, as advised in section 9.6 of the Cochrane
Handbook. We will compare the magnitude of the effects between
the subgroups by assessing the overlap of the confidence intervals
of the summary estimates. Non-overlap of the confidence intervals
indicates statistically significant differences.
Sensitivity analysis
If studies were to differ markedly from most other studies (out-
come is different) and we deem it necessary to exclude them, then
we will conduct sensitivity analyses to report whether the overall
effect changes when these studies are removed.
Where we have sufficient studies, we will perform sensitivity anal-
yses to assess the impact on primary outcomes, e.g. adverse events,
global assessment of quality, cognitive function, pain, and func-
tion of quasi-randomisation and bias attributable to unclear or
inadequate treatment allocation and blinding of the surgeon or
the outcome assessor.
Interpreting results and reaching conclusions
We will follow the guidelines in the Cochrane Handbook, Chapter
12 (Schünemann 2011b) for interpreting results, and will be aware
of distinguishing a lack of evidence of effect from a lack of effect.
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice, and our impli-
cations for research will suggest priorities for future research and
outline what the remaining uncertainties are in this area.
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A P P E N D I C E S
Appendix 1. Medline search strategy for RCTs
Ovid MEDLINE(R) 1946 to August Week 5 2016
1. arthroplasty, replacement,knee/ (17166)
2. knee Prosthesis/ (10303)
3. Tkr.ti,ab. (1338)
4. exp knee. (12724)
5. Knee.ti,ab. (96425)
6. 4 or 5 (101075)
7. exp arthroplasty/ (52275)
8. joint prosthesis/ (9921)
9. (arthroplasty$ or prosthe$ or replac$).ti,ab. (419747)
10. or/7-9 (433269)
11. 6 and 10 (29324)
12. or/1-3,11 (32468)
13. exp tourniquet/ (3407)
14. Tourniquet.ti,ab. (4412)
15. Esmarch.ti,ab (117)
16. Lofquist.ti,ab (3)
17. Cuff.ti,ab. (19634)
18. Or/13-17 (24490)
19. 12 and 18 (633)
20. randomized controlled trial.pt (430183)
21. Controlled clinical trial.ot (91662)
22. Randomized.ab. (326206)
23. Placebo.ab. (164485)
24. Clinical trials as topic.sh. (179377)
25. randomly.ab. (228844)
26. Trial.ti. (143168)
27. Or/21-26 (873089)
28. Exp animals/ not humans.sh (4313283)
29. 27 not 28 (794647)
30. 19 and 29 (192)
Appendix 2. Medline search stratedgy for observational studies
Ovid MEDLINE(R) 1946 to August Week 5 2016
1. arthroplasty, replacement,knee/ (26264)
2. knee Prosthesis/ (10437)
3. Tkr.ti,ab. (1445)
4. exp knee. (13018)
5. Knee.ti,ab. (102713)
6. 4 or 5 (107341)
7. exp arthroplasty/ (54920)
8. joint prosthesis/ (9917)
9. (arthroplasty$ or prosthe$ or replac$).ti,ab. (410606)
10. or/7-9 (446439)
11. 6 and 10 (28919)
12. or/1-3,11 (40006)
13. exp tourniquet/ (3536)
11Tourniquet use for knee replacement surgery (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
14. Tourniquet.ti,ab. (4613)
15. Esmarch.ti,ab (123)
16. Lofquist.ti,ab (4)
17. Cuff.ti,ab. (20336)
18. Or/13-17 (25912)
19. 12 and 18 (908)
20. Case-control studies/ or Case control.mp (268947)
21. Cohort studies/ or Cohort.mp (428924)
22. Case series. mp (45861)
23. Observational studies.mp or Observational study/ (57501)
24. Or/ 20-23 (749956)
25. Exp animals/ not humans.sh (4438472)
26. 24 not 25 (739494)
28. 19 and 26(85)
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